Sold as Prolixin Decanoate. Every FDA application for this active ingredient: 1 branded and 10 generic.
As of Nov 16, 2026, FDA lists 11 applications for Fluphenazine Decanoate (sold as Prolixin Decanoate), first approved Jun 20, 1972, with 0 new uses approved and 0 published complete response letters.
| Fluphenazine Decanoate | Part D | $7.5M | -6% | 10,875 |
| Fluphenazine Decanoate | Part B | $16K | -24% | 239 |
| Jun 20, 1972 | Prolixin DecanoateNDA 16727 · New active ingredient | Bristol Myers Squibb | 41 | Discontinued |
| Jul 14, 1987 | Fluphenazine DecanoateANDA 71413 | Fresenius Kabi USA | 9 | Marketed |
| Aug 30, 1996 | Fluphenazine DecanoateANDA 74531 | Hikma | 8 | Marketed |
| Sep 10, 1996 | Fluphenazine DecanoateANDA 74795 | Teva Parenteral | 0 | Discontinued |
| Apr 16, 1998 | Fluphenazine DecanoateANDA 74966 | Hospira | 1 | Discontinued |
| Aug 17, 2001 | Fluphenazine DecanoateANDA 75918 | Mylan Labs Ltd | 5 | Marketed |
| Jul 3, 2014 | Fluphenazine DecanoateANDA 203732 | Ph Health | 3 | Marketed |
| Oct 17, 2017 | Fluphenazine DecanoateANDA 207739 | Eugia Pharma | 1 | Marketed |
| Mar 30, 2023 | Fluphenazine DecanoateANDA 215509 | Gland | 1 | Marketed |
| Nov 2, 2023 | Fluphenazine DecanoateANDA 215365 | Msn | 1 | Marketed |
| — | FluphenazineANDA 70762 | Quad Pharms | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA